Skip to main content
. Author manuscript; available in PMC: 2017 Jun 19.
Published in final edited form as: Mol Neurobiol. 2015 Jan 28;53(2):1296–1309. doi: 10.1007/s12035-015-9091-8

Figure 5.

Figure 5

Immunohistofluorescence analyses of gliosis in hippocampus of Epm2b+/− (control) or Epm2b−/− (KO) mice untreated (w/o TTT) or treated with trehalose, 4-PBA or metformin (two months). (A) Representative frontal sections of the dentate gyrus (DG) and the cornus ammonis 1 (CA1) of the hippocampus from Epm2b+/− control or Epm2b−/− KO mice untreated (w/o TTT) or treated as indicated, were incubated with anti-GFAP (glial fibrillary acidic protein) antibody and AlexaFluor488 conjugated anti-rabbit antibody and counterstained with DAPI to show the area where the analysis was performed (insets). Scale bars 100 μm. GFAP-associated fluorescence was quantified with ImageJ software in two pictures from DG (B) and CA1 (C) sections from five mice per group, and mean fluorescence in an area of 0.26 mm2 was represented. Bars indicate mean of fluorescence values corresponding to five mice ± SEM. Asterisks denote significant differences *p< 0.05 ***p<0.001 comparing the indicated groups with the basal condition (Epm2b−/− w/o TTT) according to Kruskal-Wallis non-parametric test followed by Conover-Inman post-hoc test.